Premium
Plasminogen activator inhibitor type‐1 and interleukin‐6 in haemolytic uraemic syndrome
Author(s) -
Martin Aa,
Woolven Bl,
Harris Sj,
Keeley Sr,
Adams Ld,
Jureidini Kf,
Henning Ph
Publication year - 2000
Publication title -
journal of paediatrics and child health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.631
H-Index - 76
eISSN - 1440-1754
pISSN - 1034-4810
DOI - 10.1046/j.1440-1754.2000.00532.x
Subject(s) - medicine , renal function , haemolytic uraemic syndrome , plasminogen activator , gastroenterology , plasminogen activator inhibitor 1 , pediatrics , biochemistry , chemistry , escherichia coli , gene
Objective : Because haemolytic uraemic syndrome (HUS) is an important cause of renal dysfunction in children, the availability of prognostic markers of disease severity could assist in identifying those at risk of developing long‐term sequelae. The aim of this study was to test the hypothesis that plasma levels of plasminogen activator inhibitor type‐1 (PAI‐1) and interleukin‐6 (IL‐6) in children at the time of diagnosis of HUS would predict renal function outcome in terms of glomerular filtration rate (GFR). Methodology : Fourteen children suffering from diarrhoeal HUS were studied. Plasma samples were assayed for PAI‐1 and IL‐6, and GFR was measured at intervals after discharge from hospital. Twelve months following their recovery from HUS, the children were allocated to one of two outcome groups depending on whether GFR was above (Good Outcome, n = 9), or below (Poor Outcome, n = 5) 80 mL/min per 1.73 m 2 . Results : Elevated concentrations of PAI‐1 were found in 4 of 5 Poor Outcome and 4 of 9 Good Outcome children. At the same time, increased concentrations of IL‐6 were observed in 3 of 5 Poor Outcome and 3 of 9 Good Outcome children. Renal function continued to be compromised in four Poor Outcome children 36 months after diagnosis. Conclusions : Our data show that PAI‐1 and IL‐6 are elevated in the plasma of some children at the time of diagnosis of HUS, but that neither is a definitive prognostic marker of poor outcome 3 years later.